Form 4 for HUMA Humacyte, Inc.
Accepted 2022-12-19 00:00:00 ET · period of report 2022-12-16 · accession 0001818382-22-000219 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2022-12-19 | 2022-12-16 | HUMA | Ayabudge LLC | 10% | S - Sale | $2.53 | -239.5K | 17.99M | -1% | -$606.0K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-12-16 | S | D | 239,538 | $2.53 | 17,990,736 | D | — | — | (F1) On December 16, 2022, the Reporting Person sold 239,538 shares of Common Stock. The transactions enabled Mr. Brady W. Dougan, a person controlling the Reporting Person, to pay down leverage while providing a mechanism for the purchasers to acquire shares of the Issuer at a time that the Issuer was not conducting a financing transaction and was not making any additional shares available for purchase. Mr. Dougan, directly and indirectly, remains the largest shareholder of the Issuer. (F2) The price is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $2.50 to $2.63. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |